217 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
- AZI), a current global standard of care regimen In this study, zoliflodacin was safe and generally well - tolerated ; majority of adverse events were … , zoliflodacin was found to be safe and generally well - tolerated; majority of adverse events were mild to moderate with no discontinuations due
8-K
EX-99.1
avz0ozf86rmxm ym4u
6 Nov 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
ak2c7ptjxcwkaz32y2a
1 Nov 23
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:30pm
8-K
g1jmzv
11 Jul 23
Departure of Directors or Certain Officers
8:16am
8-K
EX-99.1
oqfsi8yn zb
14 Sep 22
Regulation FD Disclosure
5:22pm
SC TO-T
EX-99
mme5971sipjc99 tlixb
25 Jul 22
Third party tender offer statement
8:34am
8-K
EX-10.1
aizs4iyub bil3ehx2
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
EX-2.1
cq0h 64udpdwun3k68fd
11 Jul 22
Information about tender offer
3:46pm
SC TO-C
EX-99.1
mm6f2 2sqy38
11 Jul 22
Information about tender offer
3:46pm
8-K
EX-99.1
kkqthfx11o59cu
11 Jul 22
Innoviva to Acquire La Jolla Pharmaceutical Company
7:38am